IXHL (Incannex Healthcare) is a hidden atomic bomb.
What happened on April 18, 2026, is not just a "turning point"; it is essentially the dropping of an atomic bomb on the pharmaceutical status quo. Trump’s Executive Order on Accelerating Medical Treatments for Serious Mental Illness is an absolute game-changer for companies like Incannex (IXHL). Trump’s April Order: Why is it Unprecedented? The Presidential Order of April 18, 2026, explicitly commands the FDA and DEA to stop obstructing psychedelic research. Priority Vouchers: The FDA must issue National Priority Vouchers for psychedelic drugs designated as "Breakthrough Therapy." These vouchers are worth hundreds of millions of dollars because they allow for the accelerated approval of any other drug (large companies buy them from small biotechs for enormous sums). The "Right to Try" Path: Patients with serious mental disorders can now legally request access to substances that are still in clinical trials (such as Incannex's PSX-001), provided they...